Прививать или не прививать? или Ну, подумаешь, укол! Мифы о вакцинации. Амантонио

adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res. 2017;65(1):46-54

      18.

      Liu XC et al. Adverse events following HPV vaccination, Alberta 2006-2014. Vaccine. 2016;34(15):1800-5

      19.

      Markowitz LE et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137(3):e20151968

      20.

      Fischer S et al. Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination. Oncol Lett. 2016;12(1):601-10

      21.

      Giambi C et al. A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis. 2013;13:74

      22.

      Mollers M et al. Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands. Am J Epidemiol. 2014;179(10):1236-46

      23.

      Guo F et al. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother. 2015;11(10):2337-44

      24.

      Peter C Gøtzsche. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA. Nordic Cochrane Centre

      25.

      Brinth LS et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015; 33(22):2602-5

      26.

      Brinth L et al. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J. 2015;62(4):A5064

      27.

      Palmieri B et al. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017;65(1):106-16

      28.

      Kinoshita T et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014; 53(19):2185-200

      29.

      Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2014;21(1):135-9

      30.

      Shaw LTC. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental? Pharma Reg Affairs. 2012:S12-001

      31.

      Little DT et al. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep. 2014;2(4):2324709614556129

      32.

      DeLong G. A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus vaccine injection. J Toxicol Environ Health A. 2018; 81(14):661-74

      33.

      McInerney KA et al. the effect of vaccination against human papillomavirus on fecundability. Paediatr Perinat Epidemiol. 2017;31(6):531-6

      34.

      Gajdová M et al. Delayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats. Food Chem Toxicol. 1993;31(3):183-90

      35.

      Azmin MN et al. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol. 1985;14(3):238-42

      36.

      Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14

      37.

      Alade SL et al. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-7

      38.

      www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf

      39.

      Clinical Review of Biologics License Application Supplement for Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant (Gardasil®) to extend indication for prevention of vaginal and vulvar cancers related to HPV types 16 and 18. 2008

      40.

      Reisinger KS et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6,11,16,18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-9

      41.

      Martínez-Lavín M et al. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clin Rheumatol. 2017;36(10):2169-78

      42.

      Ozawa K et al. Suspected adverse effects after human papillomavirus vaccination: a temporal relationship between vaccine administration and the appearance of symptoms in Japan. Drug Saf. 2017;40(12):1219-29

      43.

      Jørgensen L et al. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. Systematic reviews. 2018;7(1):8

      44.

      Caulfield MJ et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin. 2007;3(4):139-45

      45.

      Lee SH. Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. J Inorg Biochem. 2012;117:85-92

      46.

      FDA Information on Gardasil – Presence of DNA Fragments Expected, No Safety Risk. 2011

      47.

      GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document Presented to VRBPAC on 18-May-2006

      48.

      Verhoeven V et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. Eur J Cancer Prev. 2013;22(1):46-51

      49.

      Hwang JH et al. Dietary supplements reduce the risk of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 2010;20(3):398-403

      50.

      Özgü E et al. Could 25-OH vitamin D deficiency be a reason for HPV infection persistence in cervical premalignant lesions? J Exp Ther Oncol. 2016;11(3):177-80

      51.

      Hernandez B et al. Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control. 2003;14(9):859-70

      52.

      Ahn W-S et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003;12(5):383-90

      53.

      Basu P et al. Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. Asian Pac J Cancer Prev. 2013;14(10):5753-9

      54.

      Mitra